1. Home
  2. CERO vs PLRZ Comparison

CERO vs PLRZ Comparison

Compare CERO & PLRZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • PLRZ
  • Stock Information
  • Founded
  • CERO 2017
  • PLRZ 2005
  • Country
  • CERO United States
  • PLRZ Israel
  • Employees
  • CERO N/A
  • PLRZ N/A
  • Industry
  • CERO
  • PLRZ
  • Sector
  • CERO
  • PLRZ
  • Exchange
  • CERO Nasdaq
  • PLRZ NYSE
  • Market Cap
  • CERO 3.5M
  • PLRZ 3.7M
  • IPO Year
  • CERO N/A
  • PLRZ 2024
  • Fundamental
  • Price
  • CERO $7.50
  • PLRZ $1.45
  • Analyst Decision
  • CERO Strong Buy
  • PLRZ
  • Analyst Count
  • CERO 2
  • PLRZ 0
  • Target Price
  • CERO $45.00
  • PLRZ N/A
  • AVG Volume (30 Days)
  • CERO 95.7K
  • PLRZ 16.0M
  • Earning Date
  • CERO 08-13-2025
  • PLRZ 02-15-2025
  • Dividend Yield
  • CERO N/A
  • PLRZ N/A
  • EPS Growth
  • CERO N/A
  • PLRZ N/A
  • EPS
  • CERO N/A
  • PLRZ N/A
  • Revenue
  • CERO N/A
  • PLRZ N/A
  • Revenue This Year
  • CERO N/A
  • PLRZ N/A
  • Revenue Next Year
  • CERO N/A
  • PLRZ N/A
  • P/E Ratio
  • CERO N/A
  • PLRZ N/A
  • Revenue Growth
  • CERO N/A
  • PLRZ N/A
  • 52 Week Low
  • CERO $6.71
  • PLRZ $0.55
  • 52 Week High
  • CERO $895.40
  • PLRZ $1,200.00
  • Technical
  • Relative Strength Index (RSI)
  • CERO 40.75
  • PLRZ N/A
  • Support Level
  • CERO $7.27
  • PLRZ N/A
  • Resistance Level
  • CERO $8.83
  • PLRZ N/A
  • Average True Range (ATR)
  • CERO 0.43
  • PLRZ 0.00
  • MACD
  • CERO -0.06
  • PLRZ 0.00
  • Stochastic Oscillator
  • CERO 13.14
  • PLRZ 0.00

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About PLRZ POLYRIZON LTD

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

Share on Social Networks: